

THE AMERICAN PSYCHIATRIC ASSOCIATION PRACTICE GUIDELINE FOR THE Pharmacological Treatment of Patients With Alcohol Use Disorder

Guideline Writing Group

Victor I. Reus, M.D., *Chair*
Laura J. Fochtmann, M.D., M.B.I., *Vice-Chair, Methodologist*
Oscar Bukstein, M.D., M.P.H.
A. Evan Eyler, M.D., M.P.H.
Donald M. Hilty, M.D.
Marcela Horvitz-Lennon, M.D., M.P.H.
Jane Mahoney, Ph.D., R.N., PMHCNS-BC
Jagoda Pasic, M.D., Ph.D.
Michael Weaver, M.D.
Cheryl D. Wills, M.D.
Jack McIntyre, M.D., *Consultant*

Systematic Review Group

Laura J. Fochtmann, M.D., M.B.I., *Methodologist*
Joel Yager, M.D.
Seung-Hee Hong

Steering Committee on Practice Guidelines

Michael J. Vergare, M.D., *Chair*
Daniel J. Anzia, M.D., *Vice-Chair*
Thomas J. Craig, M.D.
Deborah Cowley, M.D.
Laura J. Fochtmann, M.D., M.B.I., *Consultant, Methodologist*
David A. Kahn, M.D.
John M. Oldham, M.D.
Carlos N. Pato, M.D., Ph.D.
Joel Yager, M.D., *Consultant*

APA Assembly Liaisons

John P. D. Shemo, M.D., *Chair of Area Liaisons*
John M. de Figueiredo, M.D.
Marvin Koss, M.D.
Annette L. Hanson, M.D.
Bhasker Dave, M.D.
Robert M. McCarron, D.O.
Jason W. Hunziker, M.D.

APA wishes to acknowledge the contributions of APA staff (Jennifer Medicus, Seung-Hee Hong, Samantha Shugarman, Michelle Dirst, Kristin Kroeger Ptakowski). APA and the Guideline Writing Group especially thank Laura J. Fochtmann, M.D., M.B.I.; Jeremy Kidd, M.D.; Seung-Hee Hong; and Jennifer Medicus for their outstanding work and effort in developing this guideline. APA also thanks the APA Steering Committee on Practice Guidelines (Michael Vergare, M.D., Chair), liaisons from the APA Assembly for their input and assistance, and APA Councils and others for providing feedback during the comment period.

Contents

Acronyms/Abbreviations	ix
Introduction	1
Overview of the Development Process	1
Rating the Strength of Research Evidence and Recommendations	1
Proper Use of Guidelines	2
Rationale	3
Guideline Statement Summary	5
Guideline Statements and Implementation	7
Assessment and Determination of Treatment Goals	7
Statement 1: Assessment of Substance Use	7
Implementation	7
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement	8
Quality Measurement Considerations	9
Statement 2: Use of Quantitative Behavioral Measures	10
Implementation	10
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement	11
Quality Measurement Considerations	12
Statement 3: Use of Physiological Biomarkers	12
Implementation	12
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement	15
Quality Measurement Considerations	16

Statement 4: Assessment of Co-occurring Conditions	16
Implementation	16
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement	17
Quality Measurement Considerations	17
Statement 5: Determination of Initial Treatment Goals	18
Implementation	18
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement	19
Quality Measurement Considerations	19
Statement 6: Discussion of Legal Obligations	19
Implementation	19
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement	20
Quality Measurement Considerations	20
Statement 7: Review of Risks to Self and Others	21
Implementation	21
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement	21
Quality Measurement Considerations	22
Statement 8: Evidence-Based Treatment Planning	22
Implementation	22
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement	23
Quality Measurement Considerations	24
Selection of a Pharmacotherapy	25
Statement 9: Naltrexone or Acamprosate	25
Implementation	25
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement	27
Quality Measurement Considerations	28

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.